MOTS-c — compound monograph
Mitochondrial-derived 16-residue peptide. Unapproved, research supply. The Institute assesses 4 outcomes for this compound and grades the strongest at very low certainty.
§1Identification and status
§1.1Nomenclature
- Preferred name
- MOTS-c
- Compound class
- Mitochondrial-derived 16-residue peptide
- Assessment series
- Mitochondrial and metabolic cofactors
- Synonyms and codes
- mitochondrial open reading frame of the 12S rRNA type-c · MOTS-c peptide
- Route as evaluated
- Intraperitoneal and subcutaneous in preclinical studies; subcutaneous in research contexts
§1.2Chemistry
Chemical identifiers are reproduced where they are public. Where a structure has not been published the monograph records not disclosed rather than constructing one.[1]
- CAS registry number
- 1627580-64-6
- Molecular formula
- C101H152N28O22S2
- Average mass
- 2174.62
- Monoisotopic mass
- 2173.09
- ATC classification
- not assigned
§1.3Sequence and structural notes
A 16-residue peptide encoded within the mitochondrial 12S ribosomal RNA gene, one of a small family of mitochondrial-derived peptides. It contains two methionine residues, one tryptophan and two tyrosines, making it simultaneously one of the most chromophore-rich and one of the most oxidation-labile peptides in this series.
§1.4Assessment status
The Institute assesses MOTS-c across 4 indications and grades the strongest of them at very low certainty. Supplied as a research chemical; no marketing authorisation for the uses under which it is supplied.
Table 1. Assessed outcomes for MOTS-c, ordered by certainty. Each row links to the per-indication evidence extract.
| Indication | Effect as recorded | Certainty | Trials |
|---|---|---|---|
| Biological ageing and healthspan endpoints | No randomised controlled human trial identified | Very low | 0 |
| Obesity and overweight in adults | No randomised controlled human trial identified | Very low | 0 |
| Primary mitochondrial myopathy and bioenergetic disorders | No randomised controlled human trial identified | Very low | 0 |
| Type 2 diabetes mellitus | No randomised controlled human trial identified | Very low | 0 |
| Effects are reproduced as the contributing trials reported them. Where a confidence interval is held it appears on the per-indication extract rather than in this summary table. | |||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.